Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

FDA Approves Treosulfan for alloHCT Conditioning in AML and MDS

January 24th 2025

The FDA approved treosulfan plus fludarabine for alloHSCT conditioning i acute myeloid leukemia or myelodysplastic syndrome.

Nivolumab Plus Chemo Shows Long-Term OS Benefit in Chinese Patients With Advanced Gastric, GEJ, or Esophageal Cancer

January 23rd 2025

Nivolumab plus chemotherapy demonstrated long-term survival benefits in advanced gastric, GEJ, or esophageal cancer in China.

Ibrutinib/Venetoclax Combo Demonstrates Sustained TEAE-Free PFS in First-Line CLL

January 22nd 2025

Carsten Utoft Niemann, MD, PhD, discusses improvements in toxicity-free survival with ibrutinib and venetoclax in CLL.

IO-202 Plus Azacitidine Could Bring Long-Awaited Change in HMA-Naive CMML

January 22nd 2025

Gabriel Mannis, MD, discusses the observed clinical activity and manageable safety profile of IO-202 combined with azacitidine in CMML.

2024 FDA Approvals Highlight New Treatment Considerations in HR+ Breast Cancer

January 22nd 2025

Eric Winer, MD, discusses the significance of 2 FDA approvals for HR-positive, HER2-negative breast cancer and emerging novel breast cancer treatments.

FDA Grants Priority Review to RP1 Plus Nivolumab for Advanced Melanoma After Anti–PD-1 Therapy

January 21st 2025

The FDA granted priority review to the BLA for RP1 plus nivolumab in advanced melanoma following progression on an anti–PD-1 agent.

First-Line Amivantamab Plus Lazertinib Wins EU Approval for EGFR+ Advanced NSCLC

January 21st 2025

The European Commission approved first-line amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer.

Rapid, At-Home PSA Screening Test Gains Approval in UAE for Early Detection of Prostate Cancer

January 21st 2025

The Fortel PSA Screening Test has been approved by the United Arab Emirates MOHAP for the rapid detection of early signs of prostate cancer.

IMM-1-104 Plus Chemo Generates Responses in First-Line Pancreatic Cancer

January 20th 2025

First-line IMM-1-104 plus chemotherapy produced responses and disease control in patients with pancreatic cancer.

Health Canada Green Lights Fruquintinib for Metastatic Colorectal Cancer

January 20th 2025

Health Canada approved fruquintinib for select patients with metastatic colorectal cancer.

FDA Grants Breakthrough Device Designation to DCISionRT for Breast Cancer With DCIS

January 20th 2025

The FDA has granted a breakthrough device designation to the DCISionRT test for patients with breast cancer with ductal carcinoma in situ.

European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer

January 20th 2025

Frontline dostarlimab plus chemotherapy has been approved in the EU for all adult patients with primary advanced or recurrent endometrial cancer.

Development of LAVA-1207 Discontinues in mCRPC

January 20th 2025

The development of LAVA-1207 for metastatic castration-resistant prostate cancer has been discontinued.

FDA Clears Diagnostic Assay for B-Cell Lymphoma

January 20th 2025

The FDA has granted 510(k) clearance for the Ventana Kappa and Lambda Dual ISH mRNA Probe Cocktail, an assay designed to assist pathologists in diagnosing B-cell lymphoma

Retrospective Study Highlights Real-World Uptake of Bispecific Antibodies in R/R Multiple Myeloma

January 19th 2025

Ira Zackon, MD, discusses real-world observational data on bispecific antibody use in community oncology in patients with relapsed/refractory multiple myeloma.

Avapritinib Yields Improvements in Bone Density in Advanced Systemic Mastocytosis

January 17th 2025

Treatment with avapritinib was associated with dynamic changes in bone density based on lumbar T-scores among patients with systemic mastocytosis.

FDA Approves Datopotamab Deruxtecan for Unresectable or Metastatic HR+/HER2-Negative Breast Cancer

January 17th 2025

The FDA approved datopotamab deruxtecan for select unresectable or metastatic, hormone receptor–positive, HER2-negative breast cancer.

Senaparib Receives NMPA Approval As First-Line Maintenance in Ovarian Cancer

January 17th 2025

Senaparib has received marketing authorization in China as a first-line maintenance therapy for advanced ovarian cancer.

Limertinib Wins Approval in China for EGFR T790M+ NSCLC

January 17th 2025

Limertinib was approved in China for locally advanced or metastatic non–small cell lung cancer harboring an EGFR T790M mutation.

Obe-Cel Produces Durable Remissions in Adult R/R B-ALL

January 16th 2025

Obe-cel generated durable remissions in patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated during the FELIX trial.